Purple Biotech to Present New Preclinical Data on CAPTN-3 Tri-Specific Antibody Platform at ESMO-IO 2025
I'm PortAI, I can summarize articles.
Purple Biotech Ltd. will present new preclinical data on its CAPTN-3 tri-specific antibody platform at the ESMO-IO 2025 Congress in London. The presentation will focus on the platform's versatility and anti-tumor activity in treatment-resistant cancers, showcasing results from the lead program, IM1240, in PD-1 resistant models. The poster will be available on Purple Biotech's website post-congress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments